High-Dose Vitamin D3 Supplementation in the Treatment of Human Immune Deficiency Virus Patients Trial
Status:
Completed
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
High-Dose Vitamin D3 in the Treatment of Human Immune Deficiency Virus Patients, A
Double-Blind Randomized Control Trial Human immunodeficiency virus is a key challenge for
global health. Vitamin D deficiency is common in people living with HIV infection.
Antiretroviral therapy may create unique risk factors for vitamin D insufficiency, including
alterations of vitamin D metabolism by ART.